131 related articles for article (PubMed ID: 27418193)
1. Targeted re-sequencing of TET2 in Taiwanese patients with myelodysplastic/myeloproliferative neoplasms.
Lin HC; Hwang DY; Lim KH
Med Oncol; 2016 Aug; 33(8):92. PubMed ID: 27418193
[No Abstract] [Full Text] [Related]
2. A meta-analysis of TET2 mutations shows a distinct distribution pattern in de novo acute myeloid leukemia and chronic myelomonocytic leukemia.
Euba B; Vizmanos JL; García-Granero M; Aranaz P; Hurtado C; Migueliz I; Novo FJ; García-Delgado M
Leuk Lymphoma; 2012 Jun; 53(6):1230-3. PubMed ID: 22080757
[No Abstract] [Full Text] [Related]
3. Evaluation of TET2 deletions in myeloid disorders: a fluorescence in situ hybridization analysis of 109 cases.
Klaus M; Psaraki A; Mastrodemou S; Pyrovolaki K; Mavroudi I; Kalpadakis C; Papadaki HA
Leuk Res; 2011 Mar; 35(3):413-5. PubMed ID: 21087791
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
Jankowska AM; Szpurka H; Tiu RV; Makishima H; Afable M; Huh J; O'Keefe CL; Ganetzky R; McDevitt MA; Maciejewski JP
Blood; 2009 Jun; 113(25):6403-10. PubMed ID: 19372255
[TBL] [Abstract][Full Text] [Related]
5. Mutation in TET2 in myeloid cancers.
Delhommeau F; Dupont S; Della Valle V; James C; Trannoy S; Massé A; Kosmider O; Le Couedic JP; Robert F; Alberdi A; Lécluse Y; Plo I; Dreyfus FJ; Marzac C; Casadevall N; Lacombe C; Romana SP; Dessen P; Soulier J; Viguié F; Fontenay M; Vainchenker W; Bernard OA
N Engl J Med; 2009 May; 360(22):2289-301. PubMed ID: 19474426
[TBL] [Abstract][Full Text] [Related]
6. Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts.
Gelsi-Boyer V; Cervera N; Bertucci F; Brecqueville M; Finetti P; Murati A; Arnoulet C; Mozziconacci MJ; Mills KI; Cross NC; Vey N; Birnbaum D
Haematologica; 2013 Apr; 98(4):576-83. PubMed ID: 23065512
[TBL] [Abstract][Full Text] [Related]
7. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant.
Ricci C; Fermo E; Corti S; Molteni M; Faricciotti A; Cortelezzi A; Lambertenghi Deliliers G; Beran M; Onida F
Clin Cancer Res; 2010 Apr; 16(8):2246-56. PubMed ID: 20371679
[TBL] [Abstract][Full Text] [Related]
8. Next-generation sequencing of the TET2 gene in 355 MDS and CMML patients reveals low-abundance mutant clones with early origins, but indicates no definite prognostic value.
Smith AE; Mohamedali AM; Kulasekararaj A; Lim Z; Gäken J; Lea NC; Przychodzen B; Mian SA; Nasser EE; Shooter C; Westwood NB; Strupp C; Gattermann N; Maciejewski JP; Germing U; Mufti GJ
Blood; 2010 Nov; 116(19):3923-32. PubMed ID: 20693430
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of myelodysplastic/myeloproliferative neoplasms.
Reiter A; Invernizzi R; Cross NC; Cazzola M
Haematologica; 2009 Dec; 94(12):1634-8. PubMed ID: 19996113
[TBL] [Abstract][Full Text] [Related]
10. Mutation in TET2 in myeloid cancers.
Tefferi A; Lim KH; Levine R
N Engl J Med; 2009 Sep; 361(11):1117; author reply 1117-8. PubMed ID: 19741235
[No Abstract] [Full Text] [Related]
11. TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia.
Kosmider O; Gelsi-Boyer V; Ciudad M; Racoeur C; Jooste V; Vey N; Quesnel B; Fenaux P; Bastie JN; Beyne-Rauzy O; Stamatoulas A; Dreyfus F; Ifrah N; de Botton S; Vainchenker W; Bernard OA; Birnbaum D; Fontenay M; Solary E;
Haematologica; 2009 Dec; 94(12):1676-81. PubMed ID: 19797729
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of Arginase 1 is linked to DNMT3A and TET2 mutations in lower-grade myelodysplastic syndromes and chronic myelomonocytic leukemia.
Cull AH; Mahendru D; Snetsinger B; Good D; Tyryshkin K; Chesney A; Ghorab Z; Reis M; Buckstein R; Wells RA; Rauh MJ
Leuk Res; 2018 Feb; 65():5-13. PubMed ID: 29227812
[TBL] [Abstract][Full Text] [Related]
13. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
[TBL] [Abstract][Full Text] [Related]
14. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
Abdel-Wahab O; Mullally A; Hedvat C; Garcia-Manero G; Patel J; Wadleigh M; Malinge S; Yao J; Kilpivaara O; Bhat R; Huberman K; Thomas S; Dolgalev I; Heguy A; Paietta E; Le Beau MM; Beran M; Tallman MS; Ebert BL; Kantarjian HM; Stone RM; Gilliland DG; Crispino JD; Levine RL
Blood; 2009 Jul; 114(1):144-7. PubMed ID: 19420352
[TBL] [Abstract][Full Text] [Related]
15. [Mutations in TET2 in myeloid cancers].
Bernard OA; Delhommeau F; Fontenay M; Vainchenker W
Med Sci (Paris); 2009 Oct; 25(10):785-8. PubMed ID: 19849974
[No Abstract] [Full Text] [Related]
16. Phenotypic correlates and prognostic outcomes of TET2 mutations in myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes: A comprehensive study of 504 adult patients.
Coltro G; Antelo G; Lasho TL; Finke CM; Pardanani A; Gangat N; Carr RM; Binder M; Mangaonkar AA; Ketterling R; Fernandez-Zapico ME; Robertson KD; Bosi A; Vannucchi AM; Tefferi A; Patnaik MM
Am J Hematol; 2020 Apr; 95(4):E86-E89. PubMed ID: 31925810
[No Abstract] [Full Text] [Related]
17. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
Bacher U; Weissmann S; Kohlmann A; Schindela S; Alpermann T; Schnittger S; Kern W; Haferlach T; Haferlach C
Br J Haematol; 2012 Jan; 156(1):67-75. PubMed ID: 22017486
[TBL] [Abstract][Full Text] [Related]
18. [Mutation of tet2 gene and malignant blood disease].
Qian XF; Shen YF; Zhang SJ; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Aug; 18(4):1096-100. PubMed ID: 20723337
[TBL] [Abstract][Full Text] [Related]
19. Oligomonocytic chronic myelomonocytic leukemia (chronic myelomonocytic leukemia without absolute monocytosis) displays a similar clinicopathologic and mutational profile to classical chronic myelomonocytic leukemia.
Geyer JT; Tam W; Liu YC; Chen Z; Wang SA; Bueso-Ramos C; Oak J; Arber DA; Hsi E; Rogers HJ; Levinson K; Bagg A; Hassane DC; Hasserjian RP; Orazi A
Mod Pathol; 2017 Sep; 30(9):1213-1222. PubMed ID: 28548124
[TBL] [Abstract][Full Text] [Related]
20. The Interlaboratory RObustness of Next-generation sequencing (IRON) study: a deep sequencing investigation of TET2, CBL and KRAS mutations by an international consortium involving 10 laboratories.
Kohlmann A; Klein HU; Weissmann S; Bresolin S; Chaplin T; Cuppens H; Haschke-Becher E; Garicochea B; Grossmann V; Hanczaruk B; Hebestreit K; Gabriel C; Iacobucci I; Jansen JH; te Kronnie G; van de Locht L; Martinelli G; McGowan K; Schweiger MR; Timmermann B; Vandenberghe P; Young BD; Dugas M; Haferlach T
Leukemia; 2011 Dec; 25(12):1840-8. PubMed ID: 21681191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
